P19 - PSMA imaging features in oligorecurrent prostate cancer

presented by

Daniel Köhler &Tobias Maurer

Department of Diagnostic and Interventional Radiology and Nuclear Medicine , Martini-Klinik at the University Medical Center Hamburg-Eppendorf

Imaging of the prostate-specific membrane antigen (PSMA) has revolutionized prostate cancer diagnostics and therapies in the past decade. Amongst others, it led to the development of PSMA-radioguided surgery (PSMA-RGS) , a novel technique that utilizes PSMA radiotracers to identify prostate cancer manifestations intraoperatively.

Previous analyses have shown that patient selection is a key element for a successful salvage surgery. To further improve the identification of individuals who will benefit from PSMA-RGS, we analyze the influence of quantitative and qualitative imaging features of preoperative PSMA positron emission tomographies (PET) and single photon emission computed tomographies (SPECT) on clinically relevant endpoints (e.g., PSA-response, progression-free survival, etc.). This includes the use of applications like aPROMISE , a deep-learning platform developed to facilitate PSMA PET evaluation by automated segmentation and lesion assessment based on the PROMISE evaluation framework. The segmented images are also used to fit mixed multimodal models including radiomics as well as clinicopathological information to better interpret the visualization of prostate cancer manifestations on PET and SPECT. Furthermore, we seek to enhance communication between imaging specialists and surgeons by developing a lymph node map of the pelvis. The proposed approach is based on morphological landmarks on cross-sectional imaging (CT, MRI) and considers typical sites of prostate cancer metastases as well as surgical templates for lymph node resections.

Contact: d.koehler@uke.de

  • Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, van Leeuwen FWB, van Leeuwen P, de Barros H, van der Poel H, Budäus L, Steuber T, Graefen M, Tennstedt P, Heck MM, Horn T, Maurer T.Eur Urol. 2023 Jan;83(1):62-69. doi: 10.1016/j.eururo.2022.05.031. Epub 2022 Jun 17.PMID: 35718637

    Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Eur Urol. 2023 May;83(5):405-412. doi: 10.1016/j.eururo.2023.02.002. Epub 2023 Mar 17. PMID: 36935345